We believe collaboration is the key to innovation and success in the life sciences. When you partner with us to advance pharmaceutical and biotechnology innovations, we work closely with you to help improve patient outcomes through groundbreaking discoveries. Benefit from the world-class expertise and commitment of our dedicated teams and the advanced technologies in our state-of-the-art facilities. From pharmaceutical companies and biotech start-ups, to venture capital firms, non-profits and university or research institutions, we welcome the opportunity to explore joint ventures with you and your organisation.
Our broad portfolio of solutions has helped us develop strong partnerships with a variety of organisations, including top-20 pharmaceutical companies and newly launched biotechs. We adapt our support to the identified needs and regulatory requirements of each partner. Our team of scientists strive to empower our clients throughout the complex drug development process by rapidly developing and maximising the value of the IP and assets our partners put in our hands.
For pharmaceutical and biotech companies, we offer tailored solutions that address the specific needs and challenges of drug discovery and development. With over 40 years of industry expertise, our team of scientists — many of whom have extensive experience in the pharma sector — bring a deep understanding of the intricacies involved in the projects they support. Our services are designed to integrate seamlessly into our clients´ workflow at any stage, from initial target identification to clinical trials. We provide flexible entry and exit points, helping ensure that our solutions enhance your project’s value and streamline your research process. Our clients have included Vertex Pharmaceuticals, Merck KGaA, Bayer Pharma, Plectonic Biotech, Tilikum Therapeutics, Molecure SA, BioVersys, Vaderis Therapeutics, Immunic Therapeutics and many others.
De-risking compounds is crucial to bring innovative therapies to patients quickly and efficiently. We are committed to partnering with you to share and mitigate these risks. Nuvisan supports company building from the very early stages, acting both as specialist consultants for R&D and as executive partners for drug discovery and development. At our Centre of Excellence – Discovery in Berlin, formed originally as part of the drug discovery unit of Bayer Pharmaceutical, we offer comprehensive services from target identification and validation to IND-enabling studies under GLP, including hit identification, hit-to-lead, lead optimisation and DMPK profiling. As scientific consultants, we can:
Our teams support venture capitalists from the due diligence stage, offering:
Our teams are dedicated to advancing the frontiers of medical science and addressing global health challenges. We recognise the invaluable contributions of non-profit organisations and academic institutions in pioneering basic research and tackling the complexities of neglected diseases. By collaborating with these entities, we aim to support groundbreaking research efforts and expedite the development of much-needed therapies. Examples of non-profits and research institutions include: the Gates Foundation, which we support with services in the non-hormonal contraceptive research area; our participation in the Critical Assessment of Computational Hit-finding Experiments (CACHE) consortium, which seeks to enhance in silico hit identification methods for understudied biological targets using computational techniques; our oncology services supporting the research at the Deutsches Krebsforschungszentrum (DKFZ); and our commitment to the Corona Accelerated R&D in Europe (IMI-Care) consortium.
Contact Us
Search